Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Vega-Harring, Suzana M"'
Autor:
Meulendijks, Didier, Lassen, Ulrik N, Siu, Lillian L, Huitema, Alwin D R, Karanikas, Vaios, Mau-Sorensen, Morten, Jonker, Derek J, Hansen, Aaron R, Simcox, Mary E, Schostack, Kathleen J, Bottino, Dean, Zhong, Hua, Roessler, Markus, Vega-Harring, Suzana M, Jarutat, Tiantom, Geho, David, Wang, Karen, DeMario, Mark, Goss, Glenwood D, Schellens, Jan H M
PURPOSE: The TWEAK-Fn14 pathway represents a novel anticancer target that is being actively investigated. Understanding the relationship between pharmacokinetics of anti-TWEAK therapeutics and tumor pharmacodynamics is critical. We investigated expos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______101::ccea9021daede2614056a1b34b81dfe6
https://dspace.library.uu.nl/handle/1874/346853
https://dspace.library.uu.nl/handle/1874/346853
Autor:
Lassen, Ulrik N, Meulendijks, Didier, Siu, Lilian L, Karanikas, Vaios, Mau-Sorensen, Morten, Schellens, Jan H M, Jonker, Derek J, Hansen, Aaron R, Simcox, Mary E, Schostack, Kathleen J, Bottino, Dean, Zhong, Hua, Roessler, Markus, Vega-Harring, Suzana M, Jarutat, Tiantom, Geho, David, Wang, Ka, DeMario, Mark, Goss, Glenwood D, Sub Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Clinical Cancer Research, 21(2), 258. American Association for Cancer Research Inc.
Purpose: Tumor necrosis factor (TNF)–like weak inducer of apoptosis (TWEAK) and fibroblast growth factor-inducible molecule 14 (Fn14) are a ligand–receptor pair frequently overexpressed in solid tumors. TWEAK:Fn14 signaling regulates multiple onc
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Meulendijks D; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lassen UN; Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen, Denmark., Siu LL; Ontario Cancer Institute/Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Huitema AD; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Karanikas V; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Zurich, Switzerland., Mau-Sorensen M; Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen, Denmark., Jonker DJ; Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada., Hansen AR; Ontario Cancer Institute/Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Simcox ME; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York., Schostack KJ; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York., Bottino D; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York., Zhong H; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York., Roessler M; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Penzberg, Germany., Vega-Harring SM; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Penzberg, Germany., Jarutat T; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Penzberg, Germany., Geho D; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York., Wang K; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York., DeMario M; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York., Goss GD; Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada., Schellens JH; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Department of Pharmaceutical Sciences, Science Faculty, Utrecht University, Utrecht, the Netherlands. j.schellens@nki.nl.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Feb 15; Vol. 22 (4), pp. 858-67. Date of Electronic Publication: 2015 Oct 07.
Autor:
Vega Harring SM; Department of Pathology, Tokyo Medical University, Nishi-Shinjuku, Shinjuku-Ku, Tokyo 160-8402, Japan., Niyaz M, Okada S, Kudo M
Publikováno v:
Journal of cutaneous pathology [J Cutan Pathol] 2004 Sep; Vol. 31 (8), pp. 555-7.